Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril.
Azotemia produced by converting enzyme inhibition in renovascular hypertension was studied in six patients by measurement of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). Patients with unilateral renovascular hypertension lowered GFR acutely to 40% of control values at 4 hours, but after 4 days it only returned to 75% of control even though ERPF exceeded control values. Calculated filtration fraction (GFR/ERPF) decreased from 0.31 to 0.19 in 4 hours (p less than 0.05) and remained at 0.20 after 4 days of treatment despite increases in GFR and ERPF. In bilateral renovascular hypertension, neither the decreased GFR nor lowered ERPF induced by enalapril showed any tendency to return toward normal with continued treatment. These data are consistent with selective glomerular efferent arteriolar dilation in response to enalapril and suggest that angiotensin converting-enzyme inhibition interferes with the autoregulatory capacity of the kidney in the presence of severe renovascular hypertension.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects*; D004151:Dipeptides / Q000009:adverse effects* / Q000627:therapeutic use; D004656:Enalapril; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006978:Hypertension, Renovascular / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012078:Renal Artery Obstruction / Q000139:chemically induced*; D012079:Renal Circulation / Q000187:drug effects
D000959:Antihypertensive Agents; D004151:Dipeptides; D004656:Enalapril